WO1991013890A2 - Composes diastereoisomeres derivant de l'acide tetrahydrofolique, procede de preparation et utilisation dans la synthese de diastereoisomeres 6s et 6r de folates reduits - Google Patents
Composes diastereoisomeres derivant de l'acide tetrahydrofolique, procede de preparation et utilisation dans la synthese de diastereoisomeres 6s et 6r de folates reduits Download PDFInfo
- Publication number
- WO1991013890A2 WO1991013890A2 PCT/FR1991/000185 FR9100185W WO9113890A2 WO 1991013890 A2 WO1991013890 A2 WO 1991013890A2 FR 9100185 W FR9100185 W FR 9100185W WO 9113890 A2 WO9113890 A2 WO 9113890A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- formula
- tetrahydrofolic
- compound
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
Definitions
- the present invention relates to a new process for the preparation of diastereoisomeric compounds derived from tetrahydrofolic acid.
- These compounds include as industrial products (i) the mixture of diastereoisomers 6P and 6Q as defined below (and probably corresponding to formulas III and respectively IV given below), in the molar ratio 6P / 6Q of approximately 7 / 3, (ii) the pure 6P diastereomer and (iii) the pure 6Q diastereomer.
- the invention also relates to the use of said diastereoisomers 6P and 6Q in the synthesis of diastereoisomers 6S and 6R of reduced folates such as in particular 5-CHO- (6S) -THF acids,
- ( ⁇ RS) -folinic acid 5-CHO- (6RS) -THF is generally and commonly used, with its calcium salt, as a therapeutic means of "relief” in patients subjected to anti-cancer chemotherapy based on methotrexate and as a means increasing the inhibition of thymidylate synthetase by anti-cancer agents such as 5-fluorouracil and 5-fluoro-2'-deoxyuridine.
- Method II comprises the following steps: first (according to Example 5.1 of EP-A-0 348 641), (a) solubilizing said aforementioned complex salt, of formula • vs. -
- a new technical solution which allows the synthesis of diastereoisomers 6R and 6S of reduced folates to meet the aforementioned needs.
- This new technical solution differs from method II of EP-A-0 348 641 mentioned above in particular by the fact that the treatment with the anion exchange resin and then the AcOH / MeOH mixture is replaced by the reaction of 5- CHO- (6RS) -THF or [5,10- CH + - (6RS) -THF] X " with HCOOH acid at a pH in the range of 2.0 to 2.6.
- This new technical solution leads to the production of diastereoisomerically pure compounds, defined below, of configuration 6P and 6Q and very probably corresponding to formulas III and IV respectively given below.
- This technical solution constitutes a new source of access to reduced folates, since it allows in particular the preparation of dias- tereoisomerically pure such as (6S) - and ( ⁇ R) -folinic acids, (6S) - and (6R) -N 5 , N 10 -methylene-5,6,7,8- tetrahydrofolic, (6S) - and ( 6R) -N 5 -methyl-5,6,7,8-tetrahydrofolics and their salts, starting from the so-called stereoisomers of formulas III and IV.
- a process for the preparation of a compound derived from tetrahydrofolic acid and its diastereoisomers is recommended, said process being characterized in that it comprises:
- R represents the p-benzoyl- (L) -glutamic residue of formula:
- A is H; and its salts, and (ii) N 5 , N 10 -methenyl-5,6,7,8-tetrahydrofoli ⁇ acid of the formula
- X " is an anion and R is defined as above; with HCOOH at a pH in the range of 2.0 to 2.6; and
- diastereoisomer 6Q separation, from said precipitate, of a first pure diastereoisomer belonging to the series of non-natural configuration, hereinafter called diastereoisomer 6Q, and most likely corresponding to formula IV, by fractional recrystallization;
- the dotted bond connecting the nitrogen atoms N and N ⁇ has the purpose of signaling 1st that the positive charge is delocalized on the atoms N 5 , C 11 and N 10 .
- diastereoisomers 6Q, 6P and their mixtures in particular the aforementioned molar mixture 7/3.
- the 6P diastereoisomer belongs to the so-called natural series in that it leads to diastereoisomers of reduced folates such as 5-CHO- (6S) -THF, 5,10-CH- (6R) -THF,, 10-CH 2 - (6R) -THF and 5-Me- (6S) -THF, and their salts.
- the 6Q diastereoisomer belongs to the so-called unnatural series in the sense that it leads to diastereoisomers of reduced folates such as 5-CHO- (6R) -THF, ' 5,10-CH- (6S) -THF, 5 , 10-CH 2 - (6S) -THF and -Me- (6R) -THF, and their salts.
- the use of said 6P and 6Q diastereoisomers is recommended for obtaining diastereoisomerically pure reduced folates from the natural and non-natural series.
- the diastereoisomers according to the invention have been designated 6P and 6Q for convenience, since it has not been possible to directly determine their configuration. There are, however, serious reasons to assume that compound 6P is of configuration 6R and that compound 6Q is of configuration 6S; there are also serious reasons to think that these diastereoisomers are compounds of the orthoamide type and correspond to formulas III and IV, (even if in the current state of knowledge there would be hypotheses which do not link the Applicant). As indicated above, the 6P diastereoisomer belonging to the natural series very likely corresponds to the formula: H
- the R or S rating changes within each series with regard to the nomenclature rules; in the series of natural configuration we pass from the diastereoisomer 6S [for example 5- CH0- (6S) -THF or 5-Me- (6S) -THF] to the diastereoisomer 6R [for example, 10-CH- (6R) -THF or 5,10-CH 2 - (6R) -THF] when the bicyclic skeleton of the pteridinyl rest becomes tricyclic.
- the pH of the reaction medium is adjusted between 2.0 and 2.6. The adjustment of the pH within this range will advantageously be carried out by addition of NH 2 or NH 4 OH.
- the pH of the reaction medium will be between 2.2 and 2.4 and more advantageously on the order of 2.30-2.35.
- stage 1 ° the reaction of stage 1 ° will be carried out for at least 0.25 h, at a temperature of 40 to 65 ° C, and better still at a temperature of 45-60 ° C.
- stage 1) according to the invention will be implemented in two different ways:
- route (b) I> III + IV.
- ammonia is directly incorporated into the II + H 2 O / HCOOH mixture to regulate the pH, the reaction being carried out at a temperature of 55-65 ° C, for at least 0.25 h.
- route (b) compound I is reacted with an H 2 O / HC00H mixture at 60-65 ° C for at least 1 hour, the resulting reaction medium is cooled to 40-45 ° C, then the ammonia, the reaction then continuing at 40-45 ° C for at least 0.25 h.
- reaction mixture gives, on cooling to RT, a crystalline precipitate of a bright yellow color which is practically insoluble in the usual solvents.
- the crystallizations fractioned from stages 3 °) and 4 °) can be replaced by column chromatography for chiral separation.
- the anion X ⁇ of the compound of formula II will be an appropriate anion, and may in particular be chosen from the group consisting of the ions F “ , Cl “ , Br ⁇ , I “ , NO " , I / 2SO 2" , I / 3PO4 3 “” , oxalate, p-toluenesulfonate, maleate, benzenesulfonate, methanesulfonate, trifluoroacetate, and trichloroacetate.
- the orthoamides of formulas III and respectively IV can also be used for the preparation of the diastereoisomerically pure acids 5,10-CH2- (6R) -THF of formula VIII and respectively 5,10-CH 2 - (6S) -THF of formula X , and their salts, by conversion of III and IV into VII and respectively IX, then treatment with NaBH ⁇ in an aprotic solvent containing pyridine, then purification according to the teaching of Swiss patent application No. 02 736/89 of the Applicant:
- the orthoamides of formulas III and respectively IV can be used for the preparation of diastereomerically pure acids 5-Me- (6S) - THF of formula XI and respectively 5-Me- (6R) -THF of formula XII, and of their salts, by conversion to VII and respectively IX, followed by reduction with NaB ⁇ CN in an aprotic solvent:
- the salts of the diastereoisomers of natural configuration of formulas V, VIII and XI, on the one hand, and of non-natural configuration of formulas VI, X and XII, on the other hand, comprise according to the invention (i) the metal salts , especially those of alkali metals and alka- lino-earthy, such as Na, K, Ca and Mg, and (ii) the addition salts obtained with organic bases, such as in particular ethylamine, 2- (N, N-dimethylamino) ethanol, 2 - (N, N-diethylamino) ethanol, morpholine, piperidine and the like.
- the metal salts especially those of alkali metals and alka- lino-earthy, such as Na, K, Ca and Mg
- organic bases such as in particular ethylamine, 2- (N, N-dimethylamino) ethanol, 2 - (N, N-diethylamino
- Recrystallization of this mixture is carried out as follows: to a mixture of 252 ml of water and 57 ml of HCOOH with stirring, at RT and under an inert atmosphere, a sufficient quantity of NH 2 OH is added to adjust the pH to 2.3; bringing the resulting mixture to the temperature of 60 ° C and then adding said mixture III / IV 96/4; shake until complete dissolution; the resulting reaction medium is then filtered hot on Btlchner, and the filtrate is left to stand at RT for 8 h and then at 4 ° C for 60 h; the brilliant yellow solid which has precipitated is isolated by filtration, washed with water and then with acetonitrile and dried under reduced pressure for 1 h at 50 ° C.
- the resulting medium is brought to reflux for 4.5 h; 3.3 g of carbon black are added to the hot solution and the stirring is continued for 1 h while the said medium is cooled to RT.
- 87 ml of a 2M aqueous CaCl solution are added to the fitrat and the resulting solution is slowly diluted with 3.6 liters of EtOH (94%). Said solution thus diluted is kept overnight at 0 ° C., the precipitate formed is collected by filtration, washed with EtOH (94%) then MeCOMe.
- EtOH EtOH
- This product has a purity of 96% by HPLC; by repeated recrystallization using H 2 0 and drying under reduced pressure at 50 ° C, 43.5 g (rende ⁇ ment: 48.5%) of pure ( ⁇ S) -folinate are obtained. Analyzes
- This crude product is added per portion to 80 ml of water containing traces of NaOH with stirring at 0 ° C. under an inert atmosphere: during this operation the pH is maintained at approximately 9.0 by addition of NaOH IN when the time comes. 6.0 ml of a 2M aqueous MgCl solution are added to the resulting solution, which brings the pH to 8.4. The small amount of insoluble material is removed by filtration on celite. The resulting filtrate is stirred at 0 ° C while being diluted dropwise with 105 ml of acetone; after stirring for another 45 minutes at 0 ° C., the precipitate is collected by filtration, washed (twice) with acetone and dried under reduced pressure at 50 ° C for 1 h. 3.9 g of the expected magnesium salt of formula X are obtained.
- This crude product is suspended in a mixture of 37 ml of water and 0.25 ml of 2-mercaptoethanol.
- the resulting mixture is stirred at RT under an inert atmosphere and a sufficient amount of IN NaOH is added to obtain complete dissolution.
- the filtrate is filtered and acidified by adding IN HCl drop by drop to reach a pH of 3.5. After stirring the resulting suspension for 1 h at 0 ° C, centrifuging, resuspending the solid first in water, then in ethanol and finally in acetone. After drying under reduced pressure at 50 ° C for 1 h, 636 mg of the expected acid of formula XI is obtained.
- N 5 , N 10 -methylene- (6S) -5,6,7,8-tetrahydro-folic acid of formula X and its salts are diastereoisomerically pure products, belonging to the series of reduced folates of non-natural configuration, and useful in therapy. It has been found that they inhibit thymidylate synthetase and are advantageously intended for cytostatic use in therapy, in particular against cancer.
- a diastereoisomerically pure substance chosen from the group consisting of 5,10-CH 2 - (6S) -THF acid, its non-toxic salts and their mixtures, for obtaining d 'a drug inhibiting thymidylate synthetase intended for cytostatic use in therapy, in particular against cancer.
- said diastereoisomerically pure substance chosen from the group consisting of 5,10-CH2- (6S) -THF acid, its non-toxic salts and their mixtures is associated with (2) an antineoplasmic agent chosen in particular from 5-fluorouracil, 5-fluoro-2'- deoxyuridine, methotrexate, cisplatin and mixtures thereof.
- said substance (1) and said agent (2) are advantageously presented in the form of a composition in association with a physiologically acceptable excipient.
- the combination (1) + (2) offers the advantage of having synergistic effects.
- a diastereoisomerically pure substance chosen from the group consisting of (6R) - 5-formyl-5,6,7,8-tetrahydrofolic acid of formula 5- CHO- (6R) - THF, its non-toxic salts and their mixtures, for obtaining a cytostatic medicament intended for use in therapy with regard to neoplastic diseases, in particular cancer.
- each active ingredient will come at a therapeutically effective dose.
- a composition containing, in association with a physiologically acceptable excipient, a cytostatically effective amount of an active ingredient chosen.
- a composition containing, in association with a physiologically acceptable excipient, a cytostatically effective amount of an active ingredient chosen.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002056433A CA2056433A1 (fr) | 1990-03-09 | 1991-03-08 | Composes diastereoisomeres derives de l'acide tetrahydrofolique; methode de preparation et utilisation pour la synthese de diastereoisomeres 6s et 6r de folates reduits |
NO91914068A NO914068L (no) | 1990-03-09 | 1991-10-17 | Diastereomere forbindelser avledet fra tetrahydrofolsyre,deres fremstilling og anvendelse ved syntese av 6s- og 6r-diastereoisomerer av reduserte folater |
FI915254A FI915254A0 (fi) | 1990-03-09 | 1991-11-07 | Diastreoisomeriska, foereningar haerledda fraon tetrahydrofolsyra, ett foerfarande foer deras framstaellning samt anvaendning i syntes av 6s- och 6r-diastereoisomererna av reducerade folat. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR90/03032 | 1990-03-09 | ||
FR9003032A FR2659330B1 (fr) | 1990-03-09 | 1990-03-09 | Composes diastereoisomeres derivant de l'acide tetrahydrofolique, procede de preparation et utilisation dans la synthese de diastereomeres 6s et 6r de folates reduits. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1991013890A2 true WO1991013890A2 (fr) | 1991-09-19 |
WO1991013890A3 WO1991013890A3 (fr) | 1991-11-14 |
Family
ID=9394574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1991/000185 WO1991013890A2 (fr) | 1990-03-09 | 1991-03-08 | Composes diastereoisomeres derivant de l'acide tetrahydrofolique, procede de preparation et utilisation dans la synthese de diastereoisomeres 6s et 6r de folates reduits |
Country Status (8)
Country | Link |
---|---|
US (1) | US5239074A (fr) |
EP (1) | EP0471820A1 (fr) |
JP (1) | JPH04507103A (fr) |
AU (1) | AU7492591A (fr) |
CA (1) | CA2056433A1 (fr) |
FI (1) | FI915254A0 (fr) |
FR (1) | FR2659330B1 (fr) |
WO (1) | WO1991013890A2 (fr) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194611A (en) * | 1990-04-12 | 1993-03-16 | Sapec S.A. Fine Chemicals | Separation technique for a mixture of (6RS)-diastereoisomers of an ammonium salt of N5 -methyl-5,6,7,8-tetrahydrofolic acid into single (6R) and (6S)-diastereoisomers |
WO1993010118A1 (fr) * | 1991-11-11 | 1993-05-27 | Knoll Atiengesellschaft | Procede de separation de l'acide 5-methyl-tetrahydrofollique |
WO1993015076A1 (fr) * | 1992-01-22 | 1993-08-05 | Apr Applied Pharma Research S.A. | Procede de separation d'acides foliniques |
WO1993017022A1 (fr) * | 1992-02-20 | 1993-09-02 | Bracco S.P.A. | Procede de separation de stereoisomeres de l'acide folinique |
EP0600460A1 (fr) * | 1992-12-01 | 1994-06-08 | Cerbios-Pharma S.A. | Procédé pour la préparation du l'acide 6(S)-5,6,7,8-tétrahydrofolique |
WO1995007917A1 (fr) * | 1993-09-14 | 1995-03-23 | Merrell Pharmaceuticals Inc. | Derives de 5-(1-fluorovinyle)-1h-pyrimidine-2,4-dione servant d'agents anti-neoplasiques |
US5747499A (en) * | 1994-05-05 | 1998-05-05 | British Technology Group Limited | Anti-cancer compounds |
US5789417A (en) * | 1992-11-06 | 1998-08-04 | Zeneca Limited | Tricyclic compounds with pharmaceutical activity |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH684270A5 (de) * | 1991-10-04 | 1994-08-15 | Sapec Fine Chemicals | Verfahren zur Herstellung von Erdalkalimetallsalzen von (6R)-N(10)-Formyl-5,6,7,8-tetrahydrofolsäure. |
CH683690A5 (de) * | 1991-12-21 | 1994-04-29 | Sapec Fine Chemicals | Verfahren zur Herstellung von diastereoisomerenreinen Tetrahydrofolaten. |
US5698693A (en) * | 1992-11-16 | 1997-12-16 | The United States Of America As Represented By The Department Of Health And Human Services | Process of separating the diastereomers of (6R,6S) -5,6,7,8-tetrahydrofolic acid derivatives |
US5710271A (en) * | 1994-06-08 | 1998-01-20 | Dibra S.P.A. | Process for the preparation and separation of diastereomeric salts of folinic acid |
CN107304212A (zh) * | 2016-04-21 | 2017-10-31 | 常州爱诺新睿医药技术有限公司 | 一种无定型l-5-甲基四氢叶酸氨基酸盐及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2054597A (en) * | 1977-08-22 | 1981-02-18 | Us Commerce | Preparation and purification of citrovorum factor |
EP0266042A2 (fr) * | 1986-09-03 | 1988-05-04 | University of Strathclyde | Dérivés de ptéridine optiquement actifs |
EP0348641A2 (fr) * | 1988-06-29 | 1990-01-03 | EPROVA Aktiengesellschaft | Procédé de préparation de tétrahydrofolates |
EP0409125A1 (fr) * | 1989-07-21 | 1991-01-23 | Cerbios-Pharma S.A. | Sels de l'acide N5, N10-méthylène-5,6,7,8-tétrahydrofolique |
-
1990
- 1990-03-09 FR FR9003032A patent/FR2659330B1/fr not_active Expired - Fee Related
-
1991
- 1991-03-08 US US07/784,422 patent/US5239074A/en not_active Expired - Fee Related
- 1991-03-08 JP JP3505789A patent/JPH04507103A/ja active Pending
- 1991-03-08 WO PCT/FR1991/000185 patent/WO1991013890A2/fr not_active Application Discontinuation
- 1991-03-08 EP EP91905831A patent/EP0471820A1/fr not_active Withdrawn
- 1991-03-08 CA CA002056433A patent/CA2056433A1/fr not_active Abandoned
- 1991-03-08 AU AU74925/91A patent/AU7492591A/en not_active Abandoned
- 1991-11-07 FI FI915254A patent/FI915254A0/fi not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2054597A (en) * | 1977-08-22 | 1981-02-18 | Us Commerce | Preparation and purification of citrovorum factor |
EP0266042A2 (fr) * | 1986-09-03 | 1988-05-04 | University of Strathclyde | Dérivés de ptéridine optiquement actifs |
EP0348641A2 (fr) * | 1988-06-29 | 1990-01-03 | EPROVA Aktiengesellschaft | Procédé de préparation de tétrahydrofolates |
EP0409125A1 (fr) * | 1989-07-21 | 1991-01-23 | Cerbios-Pharma S.A. | Sels de l'acide N5, N10-méthylène-5,6,7,8-tétrahydrofolique |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194611A (en) * | 1990-04-12 | 1993-03-16 | Sapec S.A. Fine Chemicals | Separation technique for a mixture of (6RS)-diastereoisomers of an ammonium salt of N5 -methyl-5,6,7,8-tetrahydrofolic acid into single (6R) and (6S)-diastereoisomers |
WO1993010118A1 (fr) * | 1991-11-11 | 1993-05-27 | Knoll Atiengesellschaft | Procede de separation de l'acide 5-methyl-tetrahydrofollique |
US5457202A (en) * | 1991-11-11 | 1995-10-10 | Knoll Aktiengesellschaft | Resolution of 5-methyltetrahydrofolic acid |
WO1993015076A1 (fr) * | 1992-01-22 | 1993-08-05 | Apr Applied Pharma Research S.A. | Procede de separation d'acides foliniques |
US5391738A (en) * | 1992-01-22 | 1995-02-21 | Apr Applied Pharma Research S.A. | Process for the separation of folinic acids |
WO1993017022A1 (fr) * | 1992-02-20 | 1993-09-02 | Bracco S.P.A. | Procede de separation de stereoisomeres de l'acide folinique |
US5789417A (en) * | 1992-11-06 | 1998-08-04 | Zeneca Limited | Tricyclic compounds with pharmaceutical activity |
EP0600460A1 (fr) * | 1992-12-01 | 1994-06-08 | Cerbios-Pharma S.A. | Procédé pour la préparation du l'acide 6(S)-5,6,7,8-tétrahydrofolique |
WO1995007917A1 (fr) * | 1993-09-14 | 1995-03-23 | Merrell Pharmaceuticals Inc. | Derives de 5-(1-fluorovinyle)-1h-pyrimidine-2,4-dione servant d'agents anti-neoplasiques |
US5747499A (en) * | 1994-05-05 | 1998-05-05 | British Technology Group Limited | Anti-cancer compounds |
Also Published As
Publication number | Publication date |
---|---|
FR2659330B1 (fr) | 1994-02-11 |
US5239074A (en) | 1993-08-24 |
AU7492591A (en) | 1991-10-10 |
CA2056433A1 (fr) | 1991-09-10 |
FR2659330A1 (fr) | 1991-09-13 |
WO1991013890A3 (fr) | 1991-11-14 |
EP0471820A1 (fr) | 1992-02-26 |
FI915254A0 (fi) | 1991-11-07 |
JPH04507103A (ja) | 1992-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1287349C (fr) | Analogues de la rebeccamycine | |
US6348458B1 (en) | Polymorphic forms of olanzapine | |
WO1991013890A2 (fr) | Composes diastereoisomeres derivant de l'acide tetrahydrofolique, procede de preparation et utilisation dans la synthese de diastereoisomeres 6s et 6r de folates reduits | |
FI91157C (fi) | Menetelmä (6R,S)-folinaattien erottamiseksi | |
JPH0248577A (ja) | テトラヒドロ葉酸類の製造方法 | |
JP2000136135A (ja) | 光学活性化合物を用いた組成物 | |
BR112016004979B1 (pt) | Compostos derivados de ftalazinona, composição farmacêutica e uso do composto | |
HUT60741A (en) | Process for producing ammonium salts of n5-methyl-5,6,7,8-tetrahydrofolic acid, for separating (6rs)-diastereoisomer mixtures and for producing (6r)- and (6s)-alkali metal and alkali-earth metal salts | |
US4057548A (en) | Process for preparing methotrexate or an N-substituted derivative thereof and/or a di (lower) alkyl ester thereof and precursor therefor | |
FR2511003A1 (fr) | Alacaloides ergopeptidiques, leur preparation et leur utilisation comme medicaments | |
US4067867A (en) | Process for preparing pyrazine precursor of methotrexate or an N-substituted derivative thereof and/or a di(lower)alkyl ester thereof | |
WO2020232332A1 (fr) | Inhibiteurs de pyrrolopyrimidine de type sauvage et formes mutantes de lrrk2 | |
EP1246827B1 (fr) | Nouvelles formes polymorphes d'olanzapine | |
FR2483929A1 (fr) | Nouvelles adenosines n6-substituees utiles comme medicaments antihypertenseurs, compositions therapeutiques et formes pharmaceutiques les contenant, et leur procede de preparation | |
CZ242094A3 (en) | Process for preparing pure oxytetracycline and intermediate for the preparation thereof | |
NZ223805A (en) | Preparation of optically active oxo-isoindolinyl derivatives, and pharmaceutical compositions containing them | |
WO1992020646A1 (fr) | Nouveaux sels d'ammonium quaternaire, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant | |
EP1033362B1 (fr) | Cristaux d'acide [s,s]-ethylenediamine-n,n'-disuccinique possedant une densite volumique elevee et leur procede de preparation | |
US2568971A (en) | Preparation of substituted | |
US2470490A (en) | Process of purifying pteroylglutamic acid and related compounds | |
US7220866B2 (en) | Imidazolic compounds and use thereof as alpha-2-adrenergic receptors | |
CN115697976A (zh) | 一种氯代化合物的制备方法 | |
NZ528520A (en) | New polymorphic forms of olanzapine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA FI JP NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991905831 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2056433 Country of ref document: CA Ref document number: 915254 Country of ref document: FI |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA FI JP NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWP | Wipo information: published in national office |
Ref document number: 1991905831 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1991905831 Country of ref document: EP |